<!DOCTYPE html>
<html lang="en-US">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1.0" />
    <title>VASCEPA (icosapent ethyl) - Safety and Tolerability</title>
    <meta name="description" content="VASCEPA has a proven tolerability profile with an incidence of GI tract side effects similar to placebo, and no drug-drug interactions with warfarin, omeprazole, atorvastatin, or rosiglitazone.">
    <meta name="keywords" content="VASCEPA, safety, tolerability, eructation, fishy burp, nausea, diarrhea, drug interactions, warfarin, omeprazole, atorvastatin, rosiglitazone, HbA1c, fasting plasma glucose, A1c">
    <link rel="stylesheet" type="text/css" href="includes/style.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="includes/main.js"></script>
    <script type="text/javascript">
        if(navigator.userAgent.match(/iPad/i)) {
            viewport = document.querySelector("meta[name=viewport]");
            viewport.setAttribute('content', 'width=960');
        }
    </script>
    <script src="//use.typekit.net/kfd3zyz.js"></script>
    <script>try{Typekit.load({ async: true });}catch(e){}</script>    <script>try{Typekit.load();}catch(e){}</script>
    <script>
        (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
        (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
        m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
        })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
        ga('create', 'UA-60954107-1', 'auto');
        ga('send', 'pageview');
        
    </script>
    <script src="http://crypto-js.googlecode.com/svn/tags/3.1.2/build/rollups/sha1.js"></script>
    <script src="http://services.revhealthbackend.com/js/urlPassword.js"></script>
</head>
    
<body>
    <div id="wrapper">
        <div id="currentpg" data-current="safety"></div>
        <div id="top-content"></div>
        <div id="content" class="content-wrap">
            <div id="page-content">
                <div class="center-col no-side">
                    <div class="page-text">
                        <h1>VASCEPA Provides Proven Tolerability and an Incidence of GI Side Effects Similar to Placebo<sup>1,2</sup></h1>
                        <div class="enlarge-wrap">
                            <img class="enlarge alignnone" title="Eructation (fishy burp), Nausea, Diarrhea: table showing VASCEPA incidence of GI side effects" src="includes/uploads/Safety-Fish-chart-mobile.png" alt="Eructation (fishy burp), Nausea, Diarrhea: table showing VASCEPA incidence of GI side effects" width="1136" height="279">
                            <img class="click-img aligncenter" src="includes/uploads/Safety-Fish-chart-thumb.png" alt="Safety-(Fish)-chart-thumb" width="640" height="164">
                        </div>
                        <ul class="special-ul">
                            <li>patients taking VASCEPA 4 g/d dropped out of the MARINE trial due to adverse events</li>
                            <li style="line-height: 1">drug-drug interactions were observed in studies with:<br>
                            <span style="font-size: 11px;">&mdash; Warfarin, omeprazole, atorvastatin, or rosiglitazone</span></li>
                            <li>significant changes in fasting plasma glucose or hemoglobin&nbsp;A<sub>1c</sub> compared to the placebo group</li>
                            <li style="padding-top: 20px;">increase in LDL-C compared with placebo</li>
                        </ul>
                        
                        <div id="tolerability-profile">
                            <h2>ANCHOR TOLERABILITY PROFILE</h2>
                            <p>Adverse Reactions Occurring at an Incidence >2% and Greater Than Placebo in Double-Blind, Placebo-Controlled Trials<sup>1,</sup>*</p>
                            <div><img src="includes/uploads/anchor-tolerability-profile-chart.png" alt="Anchor Tolerability Profile Chart"></div>
                            <p class="fine">*Studies included patients from the MARINE and ANCHOR trials with TG values of 200 to 2000 mg/dL. </p>
                            <ul>
                                <li>An additional adverse reaction from clinical studies was oropharyngeal pain (<2%)</li>
                                <li>Incidences of GI side effects were similar to placebo</li>
                                <li>No significant changes were seen in fasting plasma glucose or hemoglobin A<sub>1C</sub> compared to the placebo group</li>
                                <li>No significant effects were reported with regard to liver or kidney evaluation as evidenced by ALT, AST, and creatinine kinase</li>
                            </ul>
                        </div>
                        
                        <div class="callout">
                            <h4><span class="arial"><strong>Myth/truth regarding fish oil supplements and GI side effects</strong></span></h4>
                            <p><strong>MYTH:&nbsp;</strong>All fish oil&ndash;derived products result in "fishy burps" and potential stomach irritation or diarrhea.</p>
                            <p><strong>TRUTH:&nbsp;</strong>In the MARINE trial, the safety and tolerability profile of VASCEPA was simiar to placebo. No patients taking VASCEPA 4 g/d reported "fishy burps," 1% experienced nausea, and 1% experienced diarrhea compared with 4%, 5%, and 7%, respectively, for placebo.<sup>2</sup></p>
                        </div>
                        <p><span style="font-size: 12px;">ALT, alanine transaminase; AST, aspartate transaminase; GI, gastrointestinal; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension; TG, triglyceride.</span></p>
                    </div>
                    <div class="load-disclaimer"></div>
                    <div class="references">
                        <strong>References: 1.</strong> VASCEPA [package insert]. Bedminster, NJ: Amaring Pharma Inc.; 2015. <strong>2.</strong> Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). <em>Am J Cardiol.</em> 2011;105(5):682-690.
                    </div>
                </div>
                <div class="page-sidebar">
                    <div class="load-callout"></div>
                    <div class="load-disclaimer"></div>
                </div>
            </div>
        </div>
        <div id="footer"></div>
    </div>
</body>
</html>